Sector News

AstraZeneca would consider buying immune-therapy company: Bloomberg

June 3, 2015
Life sciences
AstraZeneca Plc would consider acquiring a developer of a new type of cancer therapy aimed at supercharging the body’s immune response, Bloomberg quoted Chief Executive Pascal Soriot as saying on Tuesday.
 
An earlier version of the Bloomberg article quoted Soriot as saying that AstraZeneca would consider buying a company such as Juno Therapeutics Inc (JUNO.O).
 
Juno’s shares rose as much as 15.8 percent to $61.50 on the original report before falling back to $58.09 in early afternoon trading, for a rise of 9 percent.
 
The corrected story said Soriot was responding to a question about whether AstraZeneca was interested in making an acquisition in CAR T therapies, such as Juno.
 
“As part of our science-led strategy, we’d consider partnering with or acquiring distinctive technologies that complement our pipeline,” Esra Erkal-Palera, a spokeswoman for AstraZeneca, told Reuters.
 
“Bloomberg is citing our partnership with Juno as an example of the type of science – we don’t speculate about individual companies,” she said in an email.
 
Seattle-based Juno, among the few companies developing a new class of immuno-oncology treatments called CAR-T cell therapies, had a market value of $4.38 billion as of Monday’s close.
 
AstraZeneca and Juno already have a collaboration agreement to test one of AstraZeneca’s cancer drugs in combination with Juno’s CAR-T cell therapy, which is considered to be a breakthrough in cancer treatment.
 
CAR-T therapies, which directly recruit the immune system’s powerful T cells, are proving to be effective against tumors and could soon dominate the $100 billion global market for drugs that fight cancer.
 
AstraZeneca’s shares were up marginally at $67.31 on the New York Stock Exchange after touching a low of $66.68.
 
(Reporting by Amrutha Penumudi in Bengaluru; Editing by Ted Kerr)

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”